Unlocking Health: Benefits of Intensive Blood Pressure Control for Type 2 Diabetes Management
- A recent study from China, known as the BPROAD trial, confirmed the benefits of tighter systolic blood pressure targets for patients with type 2 diabetes.
- The trial compared two groups: one received intensive treatment aiming for a systolic blood pressure below 120 mm Hg, while the other followed standard management with a target...
- Results showed that intensive treatment led to a 0.44% lower risk of cardiovascular events per year when compared to standard management (1.65 vs.
Intensive Blood Pressure Control in Patients with Type 2 Diabetes
A recent study from China, known as the BPROAD trial, confirmed the benefits of tighter systolic blood pressure targets for patients with type 2 diabetes. The trial involved 12,821 patients and ran from February 2019 to December 2021. Participants had a mean age of 63.8 and were enrolled at 145 clinical sites across China.
The trial compared two groups: one received intensive treatment aiming for a systolic blood pressure below 120 mm Hg, while the other followed standard management with a target of 130 mm Hg. The average blood pressure achieved was 120.6 mm Hg in the intensive group and 132.1 mm Hg in the standard group.
Results showed that intensive treatment led to a 0.44% lower risk of cardiovascular events per year when compared to standard management (1.65 vs. 2.09 events per 100 person-years). Stroke was a significant factor in this difference. Patients in the intensive group experienced 21% fewer strokes, with rates of 1.19 events per 100 person-years compared to 1.50 in the standard group.
Dr. Shawna Nesbitt, a discussant from UT Southwestern Medical Center, highlighted the differences in findings from previous trials. She noted that past studies had mixed results, raising questions about the benefits of intensive blood pressure control in diabetic patients compared to non-diabetics. However, she affirmed that BPROAD confirmed that diabetic patients respond similarly to blood pressure treatments as non-diabetics.
Dr. John Buse from the University of North Carolina acknowledged past challenges in establishing the benefits of stricter blood pressure control for those with type 2 diabetes. He emphasized that the BPROAD findings represent significant progress in understanding blood pressure management in this patient group.
Current guidelines recommend a systolic blood pressure target below 130/80 mm Hg for adults with diabetes, while the American Diabetes Association suggests a target under 140/90 mm Hg for most diabetic patients. Dr. Ning from the study suggested harmonizing these guidelines to align with the tighter target set by BPROAD.
It’s important to note that type 2 diabetes in China differs from that in the U.S., with less obesity but more insulin deficiency in Chinese patients. The applicability of these findings to American patients remains uncertain.
Overall, the findings from BPROAD contribute valuable insights into blood pressure management for patients with type 2 diabetes, supporting the effectiveness of tighter targets in reducing cardiovascular risks.